A dose-ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity

Movement Disorders

Volumn 12, Issue 3, 1997, Pages 293-296

  Andreu, Nathalie ^a   Damase Michel, Christine ^a   Senard, Jean Michel ^a   Rascol, Olivier ^a   Montastruc, Jean Louis ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b INSERM   (France)

Author keywords

MAO; MAO inhibitors; Parkinson's disease; Platelets; Selegiline

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BROMOCRIPTINE; DOPA DECARBOXYLASE INHIBITOR; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; SELEGILINE; THROMBOCYTE ENZYME;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSKINESIA; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIPARKINSON AGENTS; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE; PARKINSON DISEASE; SELEGILINE;

EID: 0030913729     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870120305     Document Type: Article

References (15)

1. Heinonen EH, Lammintausta R. A review of the pharmacology of selegiline. Acta Neurol Scand 1991;84(suppI136):44-59.
2. Gerlach M, Riederer P, Youdim MBH. The molecular pharmacology of L-deprenyl. Eur J Phannacol Mol Pharmacol Sect 1992:226:97-108.
3. Chrisp P, Mammen GJ, Sorkin EM. Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging 1991;l:228-248.
4. Montastruc JL, Senard JM, Rascol O. New directions in the . drug treatment of Parkinson's disease: a review. Drugs Aging 1996;9(3):169-184.
5. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311:467-469.
6. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
7. Lees AJ, on behalf of the PDRG of UK. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild Parkinson's disease. Br Med J 1995;311:1602-1607.
8. Riederer P, Youdim MBH, Rausch WD, Birkmayer W, Jellinger K, Sieman D. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm 1978; 43:217-226.
9. Gibb WRG, Lees AJ. The relevance of Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neural Neurosurg Psychiatry 1988;51:745-752.
10. Wurtman R, Axelrod J. A sensitive and specific assay for .the estimation of monoamine oxidase. Biochem Phannacol 1963;12:1439-1441.
11. Yu P. Methods in biogenic amine research. Amsterdam: Elsevier Science, 1986.
12. Bradford MM. A rapid and sensitive method for the quantification of protein utilizing the principles of protein by binding. Ann Biochem 1976;72:248-254..
13. Golbe LI. Deprenyl as asymptomatic therapy in Parkinson's disease. Clin Netiropharmacol 1988;11:387-400.
14. Lee DH, Mendoza M, Dvorozniak MT, Chung E, Van Woert MH, Yahr MD. Platelet monoamine oxidase in Parkinson's patients: effects of L-deprenyl therapy. J Neural Transm 1989;1:189-194.
15. Oreland L, Johansson F, Eksledt J. Dose regimen of deprenyl (selegiline) and platelet MAO activities. Acta Neural Scand 1983;(suppl) 95:87-89.